HLA-DQB1(also called called IDDM1 - because of T1DM risk) is the beta 1 subunit of the HLA-DQ surface receptor, in the human MHC, part of immune regulation. It is associated with immune conditions.
Type 1 Diabetes: DQB1*0201 and DQB1*0302 are high risk, particularly together.
The HLA DQB1*06:02 form has been strongly connected with narcolepsy. [PMID 23497937]
Nearly all Celiac pateints are HLA-DQ2 and/or HLA-DQ8 positive. The highest risk was in HLA-DQB1*02 homozygosity with the HLA-DQ2.5 heterodimer (HLA-DQA1*05-DQB1*02) [PMID 25413104].
HLA-DQB1*02 was protective for breast cancer in Jordanians [PMID 24377640].
HIV-1: DQB1*06 was associated with surviving. CD4 decline was not associated with expression of the asp57 polymorphism by Vyakarnam et al. (2004). DQB1*03 and DQB1*06 are correlated with seroreversion in infants.
HLA-DQB1*0501 is associated with scleroderma in Chinese [PMID 24067471].
HLA-DQB1*03 confers susceptibility to hepatitis C in Japanese.
Myasthenia gravis (MG)susceptibility was connected to -DQ5. DQB1*05 was replicated in connection with MuSK-MG type. [PMID 23993985]
TB: DQB1*0503 has a significant association with susceptibility in Cambodians, Goldfeld et al. (1998). Delgado et al. (2006) found susceptibility was significantly associated with homozygosity of the Asp57 allele.
DQB1*0202 is possibly connected to podoconiosis.
Tag SNPs for HLA-DQB1 antitypes on the 1M Illumina chip